Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Woomera Therapeutics | Researchclopedia

Back to institutions

Woomera Therapeutics

Lebanon, New Hampshirecompany

42

Works

6,561

Citations

50

h-index

Top Research Topics

Protein Degradation and Inhibitors Ubiquitin and proteasome pathways Lymphoma Diagnosis and Treatment

Top Researchers

Wendy S. Garrett Broad Institute

267 works63,316 citationsh-index: 78

Recent Research

Targeted degradation of MK2 is insufficient to block inflammatory cytokine production in human cells due to cooperativity with MK3 and MK5

Bin Yang,Guoqiang Fang,et al.

20260 citations

Cancer-related Molecular Pathways

Neuropeptides and Animal Physiology

Chronic Lymphocytic Leukemia Research

Signaling Pathways in Disease

Cancer, Stress, Anesthesia, and Immune Response

Advanced Breast Cancer Therapies

Asthma and respiratory diseases

Bacterial Genetics and Biotechnology

Cancer Immunotherapy and Biomarkers

Dirk Walther Max Planck Institute of Molecular Plant Physiology

719 works16,636 citationsh-index: 60

157 works13,005 citationsh-index: 42

Michael Weis Rosa (United States)

159 works9,321 citationsh-index: 38

Nicholas Kwiatkowski Woomera Therapeutics

145 works8,799 citationsh-index: 43

Jing Yuan Zhejiang Chinese Medical University

261 works8,149 citationsh-index: 49

Orolabial and Genital Herpes Clinical Trials: A Meta-analysis of Endpoints

Abigail Sloan,Mahta Mortezavi,et al.

20250 citations

Developmental toxicology profile of the IRAK4 degrader KT-474

Bradley E. Enerson,Gregg D. Cappon,et al.

20251 citations

252 Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults

Arsalan Shabbir,Sagar Agarwal,et al.

20250 citations

Late Breaking Abstract - Safety, pharmacokinetics and pharmacodynamics of KT-621, an oral STAT6 degrader, in healthy adults

Arsalan Shabbir,Sagar Agarwal,et al.

20250 citations

1018eTiP A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC)

George J. Hanna,E. Sanz Garcia,et al.

20250 citations